Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Closure of Trading Window

With reference to the above captioned matter, we would like to inform you that pursuant to the Securities & Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's Code of Conduct for prohibition of insider trading ('Code') the trading window for dealing in securities of the Company will be closed for the purpose of declaration of Un-audited Financial Results of the Company for the quarter ended December 31, 2018 for all the Designated person of the Company from Monday, January 14, 2019 and shall open 48 hours after announcement of the outcome of the said meeting, for all its designated persons. Accordingly, the promoters, Directors, Designated person and all person covered under the Code have been advised not to deal in securities of the Company for the above mentioned period of closure of trading window.
12-01-2019
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results.

Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2019 ,inter alia, to consider and approve We wish to inform you that, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors of the Company is scheduled to be held on Monday, January 21, 2019 to consider and approve, inter alia, the unaudited financial results of the Company for the third quarter and nine months ended December 31, 2018. Pursuant to Company's Internal Code of Conduct for Prevention of Insider Trading, the trading window for dealing in the securities of the Company will remain closed from Monday, January 14, 2019 and shall open 48 hours after announcement of the outcome of the said meeting, for all its designated persons.
12-01-2019
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Statement Of Investor Complaints For The Quarter Ended December 2018

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Mamta MavDesignation :- Company Secretary and Compliance Officer
10-01-2019
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Shareholding for the Period Ended December 31, 2018

Aspira Pathlab & Diagnostics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click here
08-01-2019
Bigul

Announcement under Regulation 30 (LODR)-Change in Management

appointment of Dr. Haseeb Drabu as additional Independent Director
27-10-2018
Bigul

Announcement under Regulation 30 (LODR)-Resignation of Director

Resignation of Dr. Paresh Bhanushali
27-10-2018
Bigul

Financial Results 30Th September , 2018

Submission of Financial Results for 30th September , 2018
27-10-2018
Bigul

Outcome of Board Meeting

In accordance with Regulation 30 of SEBI LODR Regulations, 2015, we hereby inform you that board has appoved financial results for the quarter and half year ended 30th September, 2018.
27-10-2018
Bigul

Compliance Certificate For The Half Year Ended 30Th September, 2018

We are enclosing herewith Compliance certificate under Regulation 7(3) of SEBI Listing Obligation & Disclosure Regulations, 2015 for the half year ended 30th September, 2018.
25-10-2018
Bigul

Compliances Under Regulation 40(9) And 40(10) Of SEBI (LODR) Reguations, 2015.

We send herewith a certificate for half-year ended September 30, 2018, duly signed by Mr. S.K. Pandey, Practicing Company Secretaries, pursuant to the provisions under Regulation 40(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
24-10-2018
Next Page
Close

Let's Open Free Demat Account